Literature DB >> 12525204

High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia.

David I Kutler1, Arleen D Auerbach, Jaya Satagopan, Philip F Giampietro, Sat Dev Batish, Andrew G Huvos, Andy Goberdhan, Jatin P Shah, Bhuvanesh Singh.   

Abstract

BACKGROUND: Fanconi anemia (FA) is a rare autosomal recessive disorder characterized by a high degree of genomic instability and predisposition to cancer development. Recent evidence suggests that the incidence of head and neck squamous cell carcinoma (HNSCC) may be increased in patients with FA.
OBJECTIVE: To determine the cumulative incidence, tumor distribution, and outcome of HNSCC in patients with FA. DESIGN AND
SETTING: We analyzed data from 754 subjects from the International Fanconi Anemia Registry, a prospectively collected database of patients with FA. MAIN OUTCOME MEASURES: Cumulative incidence of HNSCC and 2-year overall, relapse-free and disease-specific survival.
RESULTS: Of the 754 patients in the International Fanconi Anemia Registry, 19 (3%) had HNSCC. This is a significantly higher incidence of HNSCC compared with that observed in the general population (standardized incidence ratio, 500; 95% confidence interval, 300-781) (P<.001). The patients' age ranged from 15 to 49 years (median, 31 years), and there was a 2:1 female predominance. Surgical treatment was well tolerated (n = 17); however, radiation therapy and chemotherapy were associated with significant morbidity and mortality. Of the 19 patients, 10 (53%) developed locoregional recurrences within a median of 16 months from diagnosis. The median follow-up was 29 months. The 2-year disease-specific, overall, and relapse-free survival rates were 49%, 49%, and 42%, respectively. The cumulative incidence of relapse by the age of 40 years was 50%.
CONCLUSIONS: In patients with FA, there is a high incidence of aggressive HNSCC at a young age. Surgery remains the mainstay of treatment because patients with FA tolerate radiation therapy and chemotherapy poorly, with significant morbidity. An increased understanding of FA-associated malignancies is not only important in the clinical management of patients with FA but can also elucidate the role of chromosomal instability in the development of HNSCC in general.

Entities:  

Mesh:

Year:  2003        PMID: 12525204     DOI: 10.1001/archotol.129.1.106

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  129 in total

1.  Postoperative clinical radiosensitivity in patients with fanconi anemia and head and neck squamous cell carcinoma.

Authors:  Andrew C Birkeland; Arleen D Auerbach; Erica Sanborn; Bhupesh Parashar; William I Kuhel; Settara C Chandrasekharappa; Agata Smogorzewska; David I Kutler
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2011-09

Review 2.  Squamous cell carcinomas of the head and neck in Fanconi anemia: risk, prevention, therapy, and the need for guidelines.

Authors:  K Scheckenbach; M Wagenmann; M Freund; J Schipper; H Hanenberg
Journal:  Klin Padiatr       Date:  2012-04-13       Impact factor: 1.349

3.  Clinical vignette: early-onset head and neck cancer: beware of fanconi anaemia!

Authors:  Rolf H Sijmons; Rein P Stulp
Journal:  Hered Cancer Clin Pract       Date:  2004-07-15       Impact factor: 2.857

4.  Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study.

Authors:  Blanche P Alter; Neelam Giri; Sharon A Savage; June A Peters; Jennifer T Loud; Lisa Leathwood; Ann G Carr; Mark H Greene; Philip S Rosenberg
Journal:  Br J Haematol       Date:  2010-04-30       Impact factor: 6.998

5.  Natural history and management of Fanconi anemia patients with head and neck cancer: A 10-year follow-up.

Authors:  David I Kutler; Krupa R Patel; Arleen D Auerbach; Jennifer Kennedy; Francis P Lach; Erica Sanborn; Marc A Cohen; William I Kuhel; Agata Smogorzewska
Journal:  Laryngoscope       Date:  2015-10-20       Impact factor: 3.325

6.  The influence of clinical and demographic risk factors on the establishment of head and neck squamous cell carcinoma cell lines.

Authors:  Jason S White; Joel L Weissfeld; Camille C R Ragin; Karen M Rossie; Christa Lese Martin; Michele Shuster; Chandramohan S Ishwad; John C Law; Eugene N Myers; Jonas T Johnson; Susanne M Gollin
Journal:  Oral Oncol       Date:  2006-11-16       Impact factor: 5.337

7.  Programmable bio-nanochip-based cytologic testing of oral potentially malignant disorders in Fanconi anemia.

Authors:  P N Floriano; T Abram; L Taylor; C Le; H Talavera; M Nguyen; R Raja; A Gillenwater; J McDevitt; N Vigneswaran
Journal:  Oral Dis       Date:  2015-04-06       Impact factor: 3.511

Review 8.  Fanconi anemia and the underlying causes of genomic instability.

Authors:  Julie Rageul; Hyungjin Kim
Journal:  Environ Mol Mutagen       Date:  2020-02-06       Impact factor: 3.216

9.  HLA-matched sibling hematopoietic stem cell transplantation for fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens.

Authors:  Ricardo Pasquini; Jeanette Carreras; Marcelo C Pasquini; Bruce M Camitta; Anders L Fasth; Gregory A Hale; Richard E Harris; Judith C Marsh; Anibal J Robinson; Mei-Jie Zhang; Mary Eapen; John E Wagner
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

Review 10.  Molecular mechanisms of head and neck cancer.

Authors:  Amit M Deshpande; David T Wong
Journal:  Expert Rev Anticancer Ther       Date:  2008-05       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.